Investor Presentaiton

Investor Presentation First six months of 2018 Slide 94 Strong growth among long-acting haemophilia B products as Refixia®/RebinynⓇ is set for launch in the EU and the USA Sales Reported recombinant FIX sales (USD million) Benefix® AlprolixⓇ RefixiaⓇ/RebinynⓇ launched in first countries IdelvionⓇ • Launched in the first EU countries in 2017 • Launched in the USA in February 2018 1,400 1,200 1,000 800 600 400 200 0 2011 CAGR: 10.1%¹ 2017 • Approved in Japan in July 2018 • RefixiaⓇ/RebinynⓇ offers a unique clinical profile that brings factor levels into the non-haemophilia range for adults and adolescents Dialogue ongoing with the FDA and EMA to establish path forward to obtain routine prophylaxis indication in the USA and complete paediatric indication in Europe to include children younger than 12 years old 1 CAGR for 6-year period FIX: Coagulation factor IX Source: Company reports (Does not include RixubisⓇ as sales are not reported separately). changing diabetes® FDA: US Food and Drug Administration; EMA: European Medicines Agency rFIX: Recombinant coagulation factor IX novo nordisk

View entire presentation